Deng Zhujun, Xiao Xia, Mou Biqin, Wang Jing, Hu Qiongxia, Jiang Juan, Xie Kang, Zhang Wengeng, Li Weimin, Chen Bojiang
Precision Medicine Center, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Precision Medicine Center, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Transl Oncol. 2025 Jul 29;60:102477. doi: 10.1016/j.tranon.2025.102477.
Much of our understanding of the germline mutation spectrum derives from hereditary breast cancer data in white populations. Additionally, the influence of genetic variants on breast cancer prognosis remains a topic of debate. Identifying patients at high risk of postoperative recurrence is crucial for guiding clinical decision-making; however, there is currently no reliable multigene risk prediction model tailored to the Chinese population.
A single-center retrospective study involving 1067 breast cancer patients was conducted. Survival analyses were performed using the Kaplan‒Meier method and Cox proportional hazards regression. Postoperative recurrence risk prediction models were developed utilizing the Cox regression methodology.
In this cohort, 229 germline pathogenic/likely pathogenic (P/LP) mutations were identified in 215 patients (20.1 %). No significant differences in disease-free survival (DFS) were observed between germline P/LP mutation carriers and non-carriers. However, 10 single-nucleotide polymorphisms (SNPs) were significantly associated with DFS outcomes. By integrating the SNP status and clinical phenotype, a postoperative recurrence risk prediction model was established. The area under the curve values for 1- and 3-year DFS in the training set were 0.840 and 0.754. This model can accurately predict the DFS of patients in both the training set (hazard ratio [HR] 5.23, 95 % confidence interval [CI] 2.96-9.34; p < 0.0001) and the validation set (HR 2.88, 95 % CI 1.41-6.06; p = 0.003) CONCLUSION: In patients with early and locally advanced breast cancer, SNPs, rather than germline P/LP mutations, impact DFS. Using a genetic-clinical model, we successfully identified patients at high risk of postoperative recurrence.
我们对种系突变谱的许多了解都来自白人群体的遗传性乳腺癌数据。此外,基因变异对乳腺癌预后的影响仍是一个有争议的话题。识别术后复发高危患者对于指导临床决策至关重要;然而,目前尚无专门针对中国人群的可靠多基因风险预测模型。
进行了一项涉及1067例乳腺癌患者的单中心回顾性研究。采用Kaplan-Meier法和Cox比例风险回归进行生存分析。利用Cox回归方法建立术后复发风险预测模型。
在该队列中,215例患者(20.1%)鉴定出229个种系致病性/可能致病性(P/LP)突变。种系P/LP突变携带者和非携带者之间未观察到无病生存期(DFS)的显著差异。然而,10个单核苷酸多态性(SNP)与DFS结果显著相关。通过整合SNP状态和临床表型,建立了术后复发风险预测模型。训练集中1年和3年DFS的曲线下面积值分别为0.840和0.754。该模型可以准确预测训练集(风险比[HR]5.23,95%置信区间[CI]2.96-9.34;p<0.0001)和验证集(HR 2.88,95%CI 1.41-6.06;p=0.003)中患者的DFS。
在早期和局部晚期乳腺癌患者中,影响DFS的是SNP,而非种系P/LP突变。我们通过一个遗传-临床模型成功识别出术后复发高危患者。